Review
Gastroenterology & Hepatology
Stephen L. Chan, Nathalie Wong, W. K. Jacky Lam, Ming Kuang
Summary: Advances in systemic treatment for hepatocellular carcinoma (HCC) have introduced more options but personalized treatment approaches are crucial due to differing patient responses. Biomarker data and tumor heterogeneity analysis have proven to be effective methods in guiding treatment decisions for HCC patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Oncology
Marina Barcena-Varela, Amaia Lujambio
Summary: Tumor heterogeneity in liver cancer significantly impacts therapeutic outcomes and complicates patient stratification and treatment selection. Understanding the various factors contributing to this heterogeneity is crucial for optimizing patient outcomes in the context of hepatocellular carcinoma.
Review
Pharmacology & Pharmacy
Marina Danilenko, Steven C. Clifford, Edward C. Schwalbe
Summary: Medulloblastoma is the most common malignant CNS tumor in children, with survivors facing lifelong late-effects from intensive treatments. Risk-stratified treatments based on better understanding of biomarkers have improved patient survival. Comprehensive understanding of disease heterogeneity within and between tumors has potential for novel therapies.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Pharmacology & Pharmacy
Hang Sun, Huayu Yang, Yilei Mao
Summary: Hepatocellular carcinoma (HCC) is a highly prevalent and fatal cancer, with limited treatment options due to late-stage diagnosis and drug resistance. Targeted therapies, such as Sorafenib and tyrosine kinase inhibitors, have shown some benefits in HCC patients. However, the disease's heterogeneity and resistance remain significant challenges. The development of patient-derived preclinical models and personalized treatment strategies offer opportunities for improved outcomes.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Sharad Khare, Tripti Khare, Raghu Ramanathan, Jamal A. Ibdah
Summary: This review discusses the role and involvement of microRNAs (miRs) in the heterogeneity and metastasis of hepatocellular carcinoma, with a special emphasis on their potential as diagnostic and prognostic tools in the risk prediction, early detection, and treatment of hepatocellular carcinoma.
Article
Pharmacology & Pharmacy
Maitane Asensio, Elisa Herraez, Rocio I. R. Macias, Elisa Lozano, Luis Munoz-Bellvis, Laura Sanchez-Vicente, Ana Morente-Carrasco, Jose J. G. Marin, Oscar Briz
Summary: Pharmacological treatment for advanced hepatocellular carcinoma (HCC) is limited in success, so this study explored the use of vectorizing drugs towards OATP1B3 to enhance their efficacy against HCC cells. Lt-OATP1B3-expressing HCC cells were more sensitive to Lt-OATP1B3 substrates, providing a basis for personalized treatment and emphasizing the importance of considering Lt-OATP1B3-mediated uptake in the design of new anti-HCC targeted drugs.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Oncology
Philip Dujardin, Anna K. Baginska, Sebastian Urban, Barbara M. Gruener
Summary: Pancreatic cancer is characterized by high heterogeneity, which can hinder personalized treatment approaches. DNA barcoding technologies have emerged as a powerful tool to study tumor heterogeneity and develop new treatment strategies.
Article
Oncology
Yuyuan Zhang, Zaoqu Liu, Jie Li, Xin Li, Mengjie Duo, Siyuan Weng, Peijie Lv, Guozhong Jiang, Caihong Wang, Yan Li, Shichao Liu, Zhen Li
Summary: This study explores the mutation patterns in hepatocellular carcinoma (HCC) and identifies two distinct mutation signature clusters. A high-risk prognosis cluster, MSC1, is characterized by activated anti-tumor immune and metabolism dysfunctional states, high genomic instability, and poor prognosis. Additionally, afatinib and canertinib drugs are found to have potential therapeutic implications in MSC1.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2023)
Article
Oncology
Yusun Park, Yeonju Han, Dongwoo Kim, Sua Cho, WonJin Kim, Hyemin Hwang, Hye Won Lee, Dai Hoon Han, Kyung Sik Kim, Mijin Yun, Misu Lee
Summary: This study examined the use of exogenous histidine treatment to enhance tumor responses to sorafenib in patients with advanced hepatocellular carcinoma (HCC). Histidine treatment reduced the expression of tumor markers related to glycolysis, inflammation, angiogenesis, and stem cells in HCC cells. Combined treatment with sorafenib and histidine may be a novel therapeutic strategy to improve the sensitivity to sorafenib and enhance long-term survival in HCC.
Article
Medicine, Research & Experimental
Ming Wu, Zijin Luo, Zhixiong Cai, Qianqian Mao, Zhenli Li, Hao Li, Cao Zhang, Yuting Zhang, Aoxue Zhong, Liming Wu, Xiaolong Liu
Summary: This study developed a strategy using red blood cells (RBCs) as carriers to deliver DNA vaccine encoding hepatocellular carcinoma (HCC) neoantigen, which effectively promoted neoantigen expression and induced T-cell immune response to prevent tumor growth. When combined with anti-PD-1, the vaccine achieved complete tumor regression and generated long-term tumor-specific immunological memory.
EMBO MOLECULAR MEDICINE
(2023)
Article
Biochemical Research Methods
Chen Yang, Xiaowen Huang, Yan Li, Junfei Chen, Yuanyuan Lv, Shixue Dai
Summary: This study retrospectively analyzed 1135 HCC patients and developed a random forest-based prediction model to estimate TP53 mutational status, as well as a robust poor prognosis-associated signature which showed superior ability to predict survival in TP53-mutant patients. In silico screening revealed three targets and two agents that might have potential therapeutic implications in high-PPS patients, presenting a comprehensive view of potential treatment strategy.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Immunology
Long Liu, Zaoqu Liu, Jie Gao, Xudong Liu, Siyuan Weng, Chunguang Guo, Bowen Hu, Zhihui Wang, Jiakai Zhang, Jihua Shi, Wenzhi Guo, Shuijun Zhang
Summary: This study identified three clusters of hepatocellular carcinoma with distinct characteristics based on the evolution of immune cells. Individualized treatment strategies were proposed for stratified patients to improve clinical outcomes and facilitate clinical management.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Mihai Ceausu, Bogdan Socea, Dragos Serban, Catalin Gabriel Smarandache, Dragos Predescu, Nicolae Bacalbasa, Iulian Slavu, Adrian Tulin, Lucian Alecu, Zenaida Ceausu
Summary: Hepatocellular carcinoma (HCC) is a primary liver cancer that is difficult to diagnose and often requires multiple microscopic techniques for confirmation. A retrospective study of 42 HCC cases revealed heterogeneity in the antigenic constellation, which can be expressed differently depending on the degree of tumor differentiation.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Engineering, Biomedical
Feihu Xie, Lejia Sun, Yuan Pang, Gang Xu, Bao Jin, Haifeng Xu, Xin Lu, Yiyao Xu, Shunda Du, Yanan Wang, Shi Feng, Xinting Sang, Shouxian Zhong, Xin Wang, Wei Sun, Haitao Zhao, Hongbing Zhang, Huayu Yang, Pengyu Huang, Yilei Mao
Summary: This study established a modeling system using three-dimensional bioprinting technology for patient-specific drug screening for hepatocellular carcinoma. The models retained features of parental HCCs, including stable biomarker expression and genetic alterations. Additionally, the models were capable of intuitively and quantitatively displaying drug screening results.
Article
Medicine, Research & Experimental
Chengli Liu, Meng Pu, Yingbo Ma, Cheng Wang, Linghong Kong, Shuhan Zhang, Xuying Zhao, Xiaopeng Lian
Summary: This study used single-cell RNA sequencing to investigate the intra-tumor heterogeneity of hepatocellular carcinoma (HCC). The researchers identified different cell subpopulations and developed a nine-gene prognostic model to assess the mortality risk of HCC patients. These findings enhance our understanding of HCC heterogeneity and could inspire future research.
EXPERIMENTAL BIOLOGY AND MEDICINE
(2022)